UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Company as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of the Exchange Act:
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
ProPhase Labs, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 20, 2022 (the “Original Report”) solely to include a description of the 2022 Directors’ Equity Compensation Plan approved by the Company’s stockholders at the Company’s 2022 Annual Meeting of Stockholders. This Amendment does not otherwise amend, update or change any other disclosure contained in the Original Report.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The 2022 Directors’ Plan provides for an increase in the number of shares reserved for issuance under the Company’s Amended and Restated 2010 Directors’ Equity Compensation Plan by 300,000 shares and provides for the adjustment of the per share exercise price of stock options granted under the 2022 Directors’ Plan in the event of any change in the outstanding shares of common stock of the Company as a result of, among other things, any distribution or special dividend to stockholders of shares, cash or other property.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ProPhase Labs, Inc. | ||
By: | /s/ Monica Brady | |
Monica Brady | ||
Chief Accounting Officer |
Date: May 23, 2022
Cover |
May 19, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | (Amendment No. 1) |
Document Period End Date | May 19, 2022 |
Entity File Number | 000-21617 |
Entity Registrant Name | PROPHASE LABS, INC. |
Entity Central Index Key | 0000868278 |
Entity Tax Identification Number | 23-2577138 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 711 Stewart Avenue |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Garden City |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 11530 |
City Area Code | (215) |
Local Phone Number | 345-0919 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0005 |
Trading Symbol | PRPH |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
M-8?20$3;8T.P6BP^0"X99K>]9!:G
4Y*PIJU+E^F>_
MHB]-2180$,LKJ;B2R6;EU%P$R0*5@7_8JLPL()[UL!%V!,)[
'DP$YF6: DYVS;G